Monoclonal 3c6f9 distribution in human breast carcinomas: image cytometry of immunocytochemical assays

  • C. Charpin
  • M. J. Dicaire
  • B. Barbeau
  • M. N. Lavaut
  • C. Andonian
  • B. Devictor
  • C. Allasia
  • P. Bonnier
  • R. Mandeville


MoAbF9 immunoreactivity was investigated in frozen sections of 123 breast carcinomas using an avidin or streptavidin biotin peroxidase kit. A standardized computer image analysis system was used to evaluate immunostaining. The percent of cell surface staining and mean optical densities were correlated with morphological criteria of prognosis such as tumor size histological grade, blood and lymph invasion and axillary lymph node involvement, with immunoreactivity to other Mo Ab, i.e. Ki67, anti-RE and anti-RP, anti-p.HER-2/ neu and with tumor aneuploidy and AgNORs content in tumor cell nuclei. Despite some heterogeneity, MoAbF9 was reactive with all breast carcinomas tested. The percent of F9 immunostained cell surface and mean optical density increased with Ki67 immunoreactivity, tumor aneuploidy and AgNORs nucleus surface but were independent of p.HER-2/neu oncoprotein distribution and tumor receptor content. These findings suggest that F9 could not only allow detection axillary lymph node micrometastases but also be used as plasmatic marker for tumor recurrence and metastases.

Key words

Monoclonal antibody F9 Image analysis Breast cancer 


  1. 1.
    Fidler D, Kripke M L: Metastasis results from preexisting variant cells within a malignant tumor.Science 197, 893–895 (1977).CrossRefPubMedGoogle Scholar
  2. 2.
    Hager J C, Russo J, Ceriani R L, Peterson J A, Fligiel S, Jolly G, Heppner G H: Epithelial characteristic of five subpopulations of a heterogeneous strain Balb/ C3H mouse mammary tumor.Cancer Res 41, 1720–1730 (1981).PubMedGoogle Scholar
  3. 3.
    Hart J R, Fidler U: The implication of tumor heterogeneity for studies on the biology and therapy of cancer metastasis.Biochim Biophys Acta 651, 37–50 (1981).PubMedGoogle Scholar
  4. 4.
    Kerbel R S: Implications of immunological heterogeneity of tumors.Nature (London) 280, 358–360 (1979).CrossRefGoogle Scholar
  5. 5.
    Mandeville R, Lecomte J, Dumas F, Vidal D, Giroux L, Chausseau J P, Ajdukovic I, Boury F: Production and characterization of monoclonal antibodies showing a different spectrum of reactivity to human breast tissue.Cancer Detect Prev 10, 129–139 (1987).PubMedGoogle Scholar
  6. 6.
    Mandeville R, Pateisky N, Scatten C, Amarouch A, Zelechowska M, Sidrac-Ghali S, Giroux L, Grouix B: Axillary lymphoscintigraphy with 123-I-labelled monoclonal antibody for the preoperative detection of lymph node metastasis in breast cancer patients, in Douillard J Y and Carrano R (eds):Monoclonal Antibodies in Clinical Oncology. Marcel Dekker, New York (1987).Google Scholar
  7. 7.
    Charpin C, Martin P, Devictor B, Lavaut M N, Habib M C, Andrac L, Toga M: Multiparametric study (SAMBA 200) of estrogen receptor immunocytochemical assay in 400 human breast carcinomas: analysis of estrogen receptor distribution heterogeneity in tissues and correlations with dextran-coated charcoal assays and morphological data.Cancer Res 48, 1578–1586 (1988).PubMedGoogle Scholar
  8. 8.
    Charpin C, Jacquemier J, Andrac L, Vacheret H, Habib M C, Devictor B, Lavaut M N, Toga M: Multiparametric analysis (SAMBA 200) of the progesterone receptor immunocytochemical assay in non-malignant and malignant disorders.Am J Path 132, 199–211, (1988).PubMedGoogle Scholar
  9. 9.
    Charpin C, Andrac L, Vacheret H, Habib M C, Devictor B, Lavaut M N, Toga M: Multiparametric evaluation (SAMBA) of growth fraction (monoclonal Ki67) in breast carcinoma tissue section.Cancer Res 48, 4368–4374 (1988).PubMedGoogle Scholar
  10. 10.
    Opfermann M, Brugal G, Vassilakos P: Cytometry of breast carcinoma: significance of ploidy balance and proliferation index.Cytometry 8, 217–224 (1897).CrossRefGoogle Scholar
  11. 11.
    Charpin C, Andrac L, Lavaut M N, Andonian C, Fraterno M, Devictor B, Perez-Castillo A, Bonnier P, Piana L: Image cytometry of aneuploidy, growth fraction (MoAb Ki67) and hormone receptors (ER, PR) immunocytochemical assays in breast carcinomas.Anal Cell Path 2, 357–371 (1990).Google Scholar
  12. 12.
    Ploton D, Ménager M, Jeannesson P, Himber G, Pigeon F, Adnett J J: Improvement in the staining and in the visualization of the argyrophil proteins of the nucleolar organized region at the optical level.J Histochem 18, 5–14 (1986).CrossRefGoogle Scholar
  13. 13.
    Gerdes J, Lelle R J, Pickartz H, Heidenneich N, Schwarting R, Kurtsiefer L, Stauch G, Stein H: Growth fractions in breast cancers determinedin situ with monoclonal antibody Ki67.J Clin Pathol 36, 977–980 (1986).CrossRefGoogle Scholar
  14. 14.
    Slamon D J, Clark G M, Wong S G, Levin W J, Ullrich A, McGuire W L: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science 235, 177–181 (1987).CrossRefPubMedGoogle Scholar
  15. 15.
    Slamon D J, Godolphin W, Jones L A, Holt J A, Wong S G, Keith D, Levin W J, Stuart S G, Udove J, Ullrich A, Press M F: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Sciences 244, 707–712 (1989).Google Scholar
  16. 16.
    World Health Organization. International tumor classification, in Breast Tumor. WHO, Geneva (1981).Google Scholar
  17. 17.
    Bloom HJG, Richardson W W: Histological grading and prognosis in breast cancer.Br J Cancer 13, 359–377 (1957).Google Scholar
  18. 18.
    King W J, Greene G L: Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells.Nature 307, 745–747 (1984).CrossRefPubMedGoogle Scholar
  19. 19.
    Greene G L, Press M F: Immunocytochemical evaluation of estrogen receptor and progesterone receptor in breast cancer, in Ceriani R L (ed):Immunological Approaches to the Diagnosis and Therapy of Breast Cancer, pp. 119–135. Plenum Press, New York (1987).Google Scholar
  20. 20.
    Charpin C, Martin P M, Jacquemier J: Estrogen receptor immunocytochemical assay (ER-ICA); computerized image analysis system, immuno-electron microscopy and comparisons with estradiol binding assays in 115 breast carcinomas.Cancer Res 46, 4271–4277 (1986).Google Scholar
  21. 21.
    Rru G: Image analysis of microscopic preparations, in Jasmin, Proschek L (eds):Methods and Achievements in Experimental Pathology, pp. 11–33. Karger, Basel (1984).Google Scholar
  22. 22.
    Brugal G: Colour processing in automated image analysis for cytology in Mary J Y, Rigaut J P (eds):Quantitative Image Analysis in Cancer Cytology and Histology, pp. 19–33. Amsterdam, Elsevier (1985).Google Scholar
  23. 23.
    Brugal G, Opfermann M, Vassilakos P: Cytoprognosis of breast carcinomas: DNA histogram pattern assessment versus nuclear chromatin texture analysis, in Mary J Y, Rigaut J P (eds):Quantitative Analysis in Cancer Cytology and Histology, pp. 142–145. Elsevier, Amsterdam (1985).Google Scholar
  24. 24.
    Seigneurin S, Brugal G, Gauvain C: A quantitative analysis of human bone marrow granulocyte cell lineage using SAMBA 200 image processor. I. The normal maturation sequence.Anal Quant Cvtol 6, 168–178 (1986).Google Scholar
  25. 25.
    Viac J, Reano A, Brochier J, Staquet M J, Thivolet J: Reactivity pattern of a monoclonal antikeratine antibody (KL1).J Invest Dermatol 81, 351–354 (1983).CrossRefPubMedGoogle Scholar
  26. 26.
    Burchell J, Durbin M, Taylor-Papadimitriou J: Complexity of expression of antigenic determinants recognized by monoclonal antibodies HMFG1 and HMFG2 in normal and malignant human mammary epithelial cells.J Immunol 131, 508–513 (1983).PubMedGoogle Scholar
  27. 27.
    Turnbull J E, Baildam A D, Barnes D M, Howell A: Molecular expression of epitopes recognized by monoclonal antibodies HMFG2 in human breast cancers: diversity variability and relationship to prognosis factors.Int J Cancer 38, 89–96 (1986).CrossRefPubMedGoogle Scholar
  28. 28.
    Taylor-Papadimitriou J, Peterson J A, Arklie J, Burchell J, Ceriani R L, Bodmer W F: Monoclonal antibodies to epithelium specific components of the human milk fat globule membrane production and reaction with cells in culture.Int J Cancer 28, 17–21 (1981).CrossRefPubMedGoogle Scholar
  29. 29.
    Hayes D F, Sekine H, Ohno T, Abe M, Keefe K, Kufe D W: Use of a murine monoclonal antibody detection of circulating plasma DF3 antigen levels in breast cancer patients.J Clin Invest 75, 1671–1678 (1985).CrossRefPubMedGoogle Scholar
  30. 30.
    Kufe D, Inghirami G, Abe M, Hayes D, Justi-Wheeler H, Schlom J: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.Hvbridoma 3, 223–232 (1984).Google Scholar
  31. 31.
    Schlom J, Wunderlich D, Teramoto Y A: Generation of human monoclonal antibodies reactive with human mammary carcinoma cells.Proc Natl Acad Sci USA 77, 6841–6845 (1980).CrossRefPubMedGoogle Scholar
  32. 32.
    Sekine H, Ohno T, Kufe D W: Purification and characterization of a high molecular weight glycoprotein detectable in human milk and breast carcinomas.J Immunol 135, 3610–3615 (1985).PubMedGoogle Scholar
  33. 33.
    Pancino G, Charpin C, Osinaga E, Betaille B, Le Roy M, Calvo F, Roseto A: Characterization and distribution in human tissues of a glycoproteic antigen defined by monoclonal antibody 1BE12 raised against the human breast cancer cell line T47D1.Cancer Res 50, 7333–7342 (1990).PubMedGoogle Scholar
  34. 34.
    Nuti M, Teramoto Y A., Mariani-Costantin R, Hand P H, Colcher D, Schlom J: A monoclonal antibody (B72-3) defines pattern of distribution of a novel tumor-associated antigen in human mammary carcinoma cell population.Int J Cancer 26, 539–545 (1982).CrossRefGoogle Scholar
  35. 35.
    Schlom J, Greiner J, Horand-Hand P., Colcher D, Inghirami G, Weeks M, Pestka S, Fisher P B, Noguchi P, Kufe D: Monoclonal antibodies to breast cancer associated antigens as potential reagents in the management of breast cancer.Cancer 54, 2777–2794 (1984).CrossRefPubMedGoogle Scholar
  36. 36.
    Colcher D, Horand-GHand P H, Nuti M, Schlom J: A spectrum of monoclonal antibodies reactive with human mammary tumor cells.Proc Natl Acad Sci USA 78, 3199–3203 (1981).CrossRefPubMedGoogle Scholar
  37. 37.
    Pancino G, Osinaga E, Vorauher W, Kakouche A, Mistro D, Charpin C, Roseto A: Production of a monoclonal antibody as immunohistochemical marker on paraffin embedded tissues using a new immunization method.Hybridoma 9, 389 (1990).PubMedCrossRefGoogle Scholar
  38. 38.
    Pancino G, Osinaga E, Charpin C, Mistro D, Barque J P, Roseto A: Purification and characterization of a breast cancer associated glycoprotein not expressed in normal breast and identified by monoclonal antibody 83D4.Br J Cancer 63, 235–242 (1991).Google Scholar
  39. 39.
    Bacus S S, Ruby S G, Weinberg D S, Chin D, Ortiz R, Bacus J W: HER-2/neu oncogene expression and proliferation in breast cancers.Am J Path 137, 103–111 (1990).PubMedGoogle Scholar

Copyright information

© Humana Press Inc. 1991

Authors and Affiliations

  • C. Charpin
    • 1
  • M. J. Dicaire
    • 2
  • B. Barbeau
    • 2
  • M. N. Lavaut
    • 1
  • C. Andonian
    • 1
  • B. Devictor
    • 1
  • C. Allasia
    • 3
  • P. Bonnier
    • 4
  • R. Mandeville
    • 2
  1. 1.Centre Hospitalo-Universitaire TimoneLaboratoire d’Anatomie Pathologique, Faculté de MédecineMarseilleFrance
  2. 2.Immunology Research Center.Institut Armand FrappierLavalCanada
  3. 3.Faculté de Médecine TimoneMarseilleDepartment of Quantitative MicroscopyFrance
  4. 4.Department of Gynecologic OncologyHopitai de la ConceptionMarseilleFrance

Personalised recommendations